References
1. Maurya S, Sarangi P, Jayandharan GR. Safety of Adeno-associated virus-based vector-mediated gene therapy-impact of vector dose. Cancer Gene Ther. 2022.
2. Aksenov S, Roberts JC, Mugundu G, Mueller KT, Bhattacharya I, Tortorici MA. Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose-Response Studies. Clin Pharmacol Ther. 2021;110(5): 1176-1179.
3. Belov A, Schultz K, Forshee R, Tegenge MA. Opportunities and challenges for applying model-informed drug development approaches to gene therapies. CPT Pharmacometrics Syst Pharmacol. 2021;10(4): 286-290.
4. West GB, Woodruff WH, Brown JH. Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals.Proc Natl Acad Sci U S A. 2002;99 Suppl 1: 2473-2478.
5. Tang F, Wong H, Ng CM. Rational Clinical Dose Selection of Adeno-Associated Virus-Mediated Gene Therapy Based on Allometric Principles. Clin Pharmacol Ther. 2021;110(3): 803-807.
6. Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep. 1970;54(2): 95-101.
7. Zou P, Yu Y, Zheng N, et al. Applications of human pharmacokinetic prediction in first-in-human dose estimation. AAPS J. 2012;14(2): 262-281.
8. Lisowski L, Staber JM, Wright JF, Valentino LA. The intersection of vector biology, gene therapy, and hemophilia. Res Pract Thromb Haemost. 2021;5(6): e12586.
9. Zou P. First-in-patient dose prediction for adeno-associated virus-mediated hemophilia gene therapy using allometric scaling. 2022, https://www.biorxiv.org/content/10.1101/2022.07.05.498837v1.article-metrics.
10. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood. 2002;99(11): 3923-3930.
11. Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood.2015;125(10): 1553-1561.
12. Terrance Hawk SL, and Timothy Morris. Formulary for Laboratory Animals : Blackwell Publishing; 2005.
13. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21): 1994-2004.
14. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25): 2357-2365.
15. Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.Nature. 2014;506(7488): 382-386.
16. Chen N, Sun K, Chemuturi NV, Cho H, Xia CQ. The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution. AAPS J.2022;24(1): 31.
17. Greig JA, Nordin JML, White JW, et al. Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques. Hum Gene Ther. 2018.
18. Monahan PE, Negrier C, Tarantino M, Valentino LA, Mingozzi F. Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia. J Clin Med. 2021;10(11).
19. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3): 342-347.
20. Amit C. Nathwani ET. Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. Blood. 2018;132(Supplement 1): 489.
21. Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27(6): 947-956.
22. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020;382(1): 29-40.
23. Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med. 2017;377(26): 2519-2530.
24. George LA, Monahan PE, Eyster ME, et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021;385(21): 1961-1973.